Moderna (MRNA - Free Report) closed the most recent trading day at $168.10, moving -0.83% from the previous trading session. This change was narrower than the S&P 500's 0.92% loss on the day.
Prior to today's trading, shares of the biotechnology company had gained 14.84% over the past month. This has outpaced the Medical sector's gain of 0.12% and the S&P 500's gain of 6.83% in that time.
MRNA will be looking to display strength as it nears its next earnings release, which is expected to be May 6, 2021. The company is expected to report EPS of $2.36, up 774.29% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $2.2 billion, up 26088.62% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $23.46 per share and revenue of $17.01 billion. These totals would mark changes of +1296.94% and +2017.52%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for MRNA. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.27% higher. MRNA is currently a Zacks Rank #3 (Hold).
Investors should also note MRNA's current valuation metrics, including its Forward P/E ratio of 6.77. For comparison, its industry has an average Forward P/E of 26.2, which means MRNA is trading at a discount to the group.
It is also worth noting that MRNA currently has a PEG ratio of 0.67. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.51 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 205, putting it in the bottom 20% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Moderna (MRNA - Free Report) closed the most recent trading day at $168.10, moving -0.83% from the previous trading session. This change was narrower than the S&P 500's 0.92% loss on the day.
Prior to today's trading, shares of the biotechnology company had gained 14.84% over the past month. This has outpaced the Medical sector's gain of 0.12% and the S&P 500's gain of 6.83% in that time.
MRNA will be looking to display strength as it nears its next earnings release, which is expected to be May 6, 2021. The company is expected to report EPS of $2.36, up 774.29% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $2.2 billion, up 26088.62% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $23.46 per share and revenue of $17.01 billion. These totals would mark changes of +1296.94% and +2017.52%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for MRNA. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.27% higher. MRNA is currently a Zacks Rank #3 (Hold).
Investors should also note MRNA's current valuation metrics, including its Forward P/E ratio of 6.77. For comparison, its industry has an average Forward P/E of 26.2, which means MRNA is trading at a discount to the group.
It is also worth noting that MRNA currently has a PEG ratio of 0.67. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.51 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 205, putting it in the bottom 20% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MRNA - FREE